Latest Updates

The dossier on Siddha was in the making for several years under the Central Council for Research in Siddha

The primary outcome was hospital mortality, adjusted for age, ethnicity, comorbid disease, severity of illness, socioeconomic…

The patents are valid through 2023 and 2034

DUSA filed a motion for preliminary injunctive relief in November 2018 requesting an order prohibiting Biofrontera from using…

The study will now monitor here women implanted with the devices for five years, up from three years, and would need additional…

Elzonris will be commercially available in early 2019

The setbacks come at a time when the drug is competing against other immunotherapy cancer drugs such as Merck & Co’s Keytruda,…

The product will be launched in Q4FY19

Discussions were held on how in the coming months the sector will see stricter implementation of quality standards and increased…

To develop and commercialise a novel oncology drug to treat haematological cancers

Accept the need that a better working relationship between industry and regulators is crucial for future progress

Urges that building trust in India's medicines and positive image of regulators is the need of the hour

Hope that in the coming years India will contribute significantly to the growth of the biosimilars sector globally

The session addresses aspects such as data security, affordability of medical devices, impact on healthcare outcomes and…

Stress on the need to bring innovation in the IPR framework

Inspire students to follow their dreams and withstand any challenges in their quest to success

Advocate that AMR needs a one health approach for both humans and animals, at both the national and global levels

Discussions were held on regulations of medical devices and role of state regulatory authorities

To discuss issues on APIs, generic formulations, diagnostics and medical devices, biosimilars, pharmacovigilance; clinical…

He will take charge from Dilip Shanghvi, the current President of 70th edition of IPC